Coming Soon
NOW FDA APPROVED
Announcing the first and only prescription app for the treatment of postpartum depression symptoms
What is MamaLift Plus?
MamaLift Plus is a prescription‐only digital therapeutic intended to provide neurobehavioral interventions to patients 22 years of age and older, as an adjunct to clinician‐managed outpatient care. MamaLift Plus treats mild to moderate postpartum depression by improving a patient’s symptoms of depression.
In a clinical trial, MamaLift Plus resulted in:
Reduced symptoms of postpartum depression
Find out more in the press release for MamaLift Plus
MamaLift Plus will be available in summer 2024 for download on the App Store® or Google Play™.
App Store is a service mark of Apple Inc., registered in the United States and other countries.
Google Play and the Google Play logo are trademarks of Google LLC.
INDICATION FOR USE: MamaLift Plus is a prescription‐only digital therapeutic intended to provide neurobehavioral interventions to patients 22 years of age and older, as an adjunct to clinician‐managed outpatient care. MamaLift Plus treats mild to moderate postpartum depression by improving a patient’s symptoms of depression.
SAFETY INFORMATION: MamaLift Plus is not intended to be used as a stand-alone treatment. MamaLift Plus may not be appropriate for everyone. Patients with severe depression or anxiety, Serious Mental Illness (SMI), psychosis, thoughts of harming themselves or others, or who are under the age of 22 should not use MamaLift Plus. Patients should dial 911 or go to the nearest emergency room in the event of a medical emergency. Use of MamaLift Plus should be undertaken only under the supervised care of a Health Care Provider.